Safety, Tolerability, and Pharmacokinetics of APN1125 in Subjects With Schizophrenia
Status:
Suspended
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study in patients with schizophrenia is to evaluate the safety,
tolerability, and pharmacokinetics of 3 doses (low, mid, high) of APN1125 compared with
placebo when administered as repeated daily oral doses.